Results 1 to 10 of about 6,658 (202)

Rucaparib for PARP Inhibitor-Pretreated Ovarian Cancer: A GEICO Retrospective Subgroup Analysis From the Spanish Rucaparib Access Program [PDF]

Gynecologic Oncology Reports, 2023
The poly(ADP-ribose) polymerase inhibitor (PARPi) rucaparib is approved as maintenance therapy for patients with platinum-sensitive recurrent high-grade ovarian cancer (HGOC).
Raúl Márquez, Ana Santaballa, Alfonso Yubero   +2 more
exaly   +4 more sources

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study [PDF]

BMC Cancer, 2022
Background: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Rucaparib Access Programme (RAP) was designed to provide early access to rucaparib
Alfonso Yubero, Aranzazu Barquín, Purificación Estévez, Bella Pajares, Luisa Sánchez, Piedad Reche, Jesús Alarcón, Julia Calzas, Lydia Gaba, José Fuentes, Ana Santaballa, Carmen Salvador, Luis Manso, Ana Herrero, Álvaro Taus, Raúl Márquez, Julia Madani, María Merino, Gloria Marquina, Victoria Casado, Manuel Constenla, María Gutiérrez, Alba Dosil, Antonio González-Martín   +23 more
doaj   +17 more sources

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data

BMC Cancer, 2023
Background Rucaparib has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. However, the long-term safety of rucaparib in large sample population was unknown. The
Qilin Zhang, Yiling Ding, Yamin Shu, Jing Chen   +3 more
doaj   +2 more sources

Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself. [PDF]

PLoS ONE, 2015
Therapeutic inhibition of poly(ADP-ribose) polymerase (PARP), as monotherapy or to supplement the potencies of other agents, is a promising strategy in cancer treatment.
Cian M McCrudden, Martin G O'Rourke, Kim E Cherry, Hiu-Fung Yuen, Declan O'Rourke, Muhammad Babur, Brian A Telfer, Huw D Thomas, Patrick Keane, Thiagarajan Nambirajan, Chris Hagan, Joe M O'Sullivan, Chris Shaw, Kaye J Williams, Nicola J Curtin, David G Hirst, Tracy Robson   +16 more
doaj   +3 more sources

Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors [PDF]

Nature Communications
For all drugs, effective target engagement requires sufficient intracellular concentrations of drug to be reached, but whether tumour heterogeneity impacts drug distribution and efficacy is poorly studied.
Carmen R. Moncayo, Restuadi Restuadi, Guanying Zhang, Daniel Marks, Paula Ortega-Prieto, Emily Doherty, Nathalie Lambie, Chad Whilding, Ivan Andrew, Alex Montoya, Bhavik Patel, Katie Tyson, Betheney R. Pennycook, Lauren Pendergast, Vincen Wu, Zoltan Takats, Nik Matthews, George R. Young, Priyanka Verma, Pavel Shliaha, Laurence Game, Boris Lenhard, Iain McNeish, Christina Fotopoulou, Alexis R. Barr, Paula Cunnea, Zoe Hall, Louise Fets   +27 more
doaj   +2 more sources

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status [PDF]

Cells, 2021
Background: Approximately 50% of ovarian cancer patients harbour homologous recombination repair deficiencies. These deficiencies have been successfully targeted using poly (ADP-ribose) polymerase inhibitors (PARPi) particularly for patients harbouring ...
Sayeh Saravi, Zena Alizzi, Sabrina Tosi, Marcia Hall, Emmanouil Karteris   +4 more
doaj   +2 more sources

Rucaparib in Ovarian Cancer: An Update on Safety, Efficacy and Place in Therapy

Therapeutic Advances in Medical Oncology, 2018
Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma,
Robert L Coleman, Graziela Z Dal Molin, Anil K. Sood   +2 more
exaly   +2 more sources

Development of Mitochondria-Targeted PARP Inhibitors [PDF]

Biomolecules
PARP inhibitors are a clinically validated class of anticancer therapeutics that exploit synthetic lethality to target homologous recombination-deficient tumors, such as those carrying BRCA1/2 mutations.
Pavels Dimitrijevs, Marina Makrecka-Kuka, Pavel Arsenyan   +2 more
doaj   +2 more sources

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Cancer Medicine, 2021
Background The efficacy and safety of rucaparib maintenance treatment in ARIEL3 were evaluated in subgroups based on best response to most recent platinum‐based chemotherapy and baseline disease.
Ana Oaknin, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Leary, Robert W. Holloway, Margarita Amenedo Gancedo, Peter C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Susana Banerjee, Jesus García‐Donas, Elizabeth M. Swisher, Terri Cameron, Lara Maloney, Sandra Goble, Jonathan A. Ledermann, Robert L. Coleman   +23 more
doaj   +1 more source

Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis

Frontiers in Oncology, 2022
ObjectiveThis study aims to compare the efficacy and safety of different poly (ADP-ribose) polymerase (PARP) inhibitors in patients with ovarian cancer through a network meta-analysis to support clinical treatment choices.MethodsThe Cochrane Library ...
Jing Luo, Shunlong Ou, Hua Wei, Xiaoli Qin, Qian Jiang   +4 more
doaj   +1 more source